<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02425306</url>
  </required_header>
  <id_info>
    <org_study_id>17860</org_study_id>
    <nct_id>NCT02425306</nct_id>
  </id_info>
  <brief_title>Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma</brief_title>
  <acronym>Mel63; CHAMP</acronym>
  <official_title>A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research Institute, New York City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether it is safe to administer a peptide vaccine in combination with&#xD;
      different adjuvants. Adjuvants are substances that may boost immune responses vaccines. In&#xD;
      this study, the adjuvants are Montanide ISA-51, polyICLC and cyclophosphamide. This study&#xD;
      will also evaluate the effects of the combination of the peptide vaccine and the adjuvants on&#xD;
      the immune system. The investigators will monitor these effects by performing tests in the&#xD;
      laboratory on participants' blood, a lymph node, and tissue from the sites of vaccination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual to part 2 of the study. Accrual to part 1 is complete.&#xD;
  </why_stopped>
  <start_date type="Actual">May 12, 2015</start_date>
  <completion_date type="Actual">January 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 18, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>30 days after administration of the last dose of 6MHP or cyclophosphamide</time_frame>
    <description>Treatment-related adverse events, by CTCAE v4, Dose-limiting toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity-CD4+ T Cell Responses</measure>
    <time_frame>through day 85</time_frame>
    <description>CD4+ T cell responses to 6 MHP: durable helper T cell response to 6MHP at 2 or more consecutive timepoints in the PBMC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity-modification of the Tumor Microenvironment (Part 2 Only)</measure>
    <time_frame>through day 22</time_frame>
    <description>increased infiltration of CD4+ and CD8+ T lymphocytes into melanoma metastases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity-CD8+ T Cell Responses</measure>
    <time_frame>through day 85</time_frame>
    <description>CD8+ T cell responses to defined melanoma antigens</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm A:6MHP + Montanide ISA-51</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C:6MHP + polyICLC + Montanide ISA-51</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>6MHP</intervention_name>
    <description>6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides</description>
    <arm_group_label>Arm A:6MHP + Montanide ISA-51</arm_group_label>
    <arm_group_label>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
    <arm_group_label>Arm C:6MHP + polyICLC + Montanide ISA-51</arm_group_label>
    <arm_group_label>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
    <other_name>6 melanoma helper peptide vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montanide ISA-51</intervention_name>
    <description>Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant</description>
    <arm_group_label>Arm A:6MHP + Montanide ISA-51</arm_group_label>
    <arm_group_label>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
    <arm_group_label>Arm C:6MHP + polyICLC + Montanide ISA-51</arm_group_label>
    <arm_group_label>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polyICLC</intervention_name>
    <description>polyICLC, local adjuvant</description>
    <arm_group_label>Arm C:6MHP + polyICLC + Montanide ISA-51</arm_group_label>
    <arm_group_label>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide, systemic adjuvant</description>
    <arm_group_label>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
    <arm_group_label>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part 1 only: Participants with stage IIB, IIC, III, or IV melanoma at original&#xD;
             diagnosis or at restaging after recurrence. Patients with high-risk stage IIA melanoma&#xD;
             (by DecisionDx Melanoma test, Castle Biosciences, Inc,;Friendswood, TX) also may be&#xD;
             eligible. These participants may have had cutaneous, uveal, mucosal primary melanoma,&#xD;
             or an unknown primary melanoma. Diagnosis of melanoma must be confirmed by cytological&#xD;
             or histological examination. Staging of cutaneous melanoma will be based on version 7&#xD;
             AJCC staging system.&#xD;
&#xD;
          -  Part 2 only: Patients with a diagnosis of stage IIIB-IV melanoma with one or more&#xD;
             tumor deposits accessible for biopsy and/or excision. These participants may have had&#xD;
             cutaneous, uveal, mucosal primary melanoma, or an unknown primary melanoma. Diagnosis&#xD;
             of melanoma must be confirmed by cytological or histological examination. Staging of&#xD;
             cutaneous melanoma will be based on version 7 AJCC staging system.&#xD;
&#xD;
        Patients must have adequate cutaneous, subcutaneous, soft tissue, or nodal metastases of&#xD;
        melanoma readily accessible for biopsy&#xD;
&#xD;
          -  Participants will be required to have radiological studies to rule out radiologically&#xD;
             evident disease. Required studies include:&#xD;
&#xD;
               -  Chest CT scan,&#xD;
&#xD;
               -  Abdominal and pelvic CT scan, and&#xD;
&#xD;
               -  Head CT scan or MRI&#xD;
&#xD;
               -  PET/CT fusion scan may replace scans of the chest, abdomen, and pelvis.&#xD;
&#xD;
          -  Participants who have had brain metastases will be eligible if all of the following&#xD;
             are true:&#xD;
&#xD;
               -  Each brain metastasis must have been completely removed by surgery or each&#xD;
                  unresected brain metastasis must have been treated with stereotactic&#xD;
                  radiosurgery.&#xD;
&#xD;
               -  There has been no evident growth of any brain metastasis since the most recent&#xD;
                  treatment.&#xD;
&#xD;
               -  No brain metastasis is &gt; 2 cm in diameter at the time of registration.&#xD;
&#xD;
               -  The most recent surgical resections or gamma-knife therapy for malignant melanoma&#xD;
                  must have been completed ≥ 1 week and for Part 1, ≤ 6 months prior to&#xD;
                  registration.&#xD;
&#xD;
          -  All participants must have:&#xD;
&#xD;
               -  ECOG performance status of 0 or 1 (Appendix 3)&#xD;
&#xD;
               -  Ability and willingness to give informed consent&#xD;
&#xD;
          -  Laboratory parameters as follows:&#xD;
&#xD;
               -  ANC &gt; 1000/mm3&#xD;
&#xD;
               -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
               -  Hgb &gt; 9 g/dL&#xD;
&#xD;
               -  HgbA1c ≤ 7.5%&#xD;
&#xD;
               -  Hepatic:&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 x upper limits of normal (ULN)&#xD;
&#xD;
               -  Bilirubin ≤ 2.5 x ULN (except in patients with Gilbert's disease, where bilirubin&#xD;
                  to 4x ULN is allowed)&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               -  Serology (within 6 months of study entry)&#xD;
&#xD;
               -  HIV negative&#xD;
&#xD;
               -  Hepatitis C negative (no evidence of active virus)&#xD;
&#xD;
          -  Blood is to be collected for HLA typing (Class I and Class II), which will be analyzed&#xD;
             as part of the immunologic endpoints, but HLA type will not be an inclusion/exclusion&#xD;
             criterion.&#xD;
&#xD;
          -  Age 18 years or older at registration.&#xD;
&#xD;
          -  Part 1 only: Participants must have at least two intact (undissected) axillary and/or&#xD;
             inguinal lymph node basins.&#xD;
&#xD;
          -  Part 2 only: Participants must have at least one intact (undissected) axillary and/or&#xD;
             inguinal lymph node basin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have received the following medications or treatments at any time&#xD;
             within 4 weeks of registration:&#xD;
&#xD;
               -  Chemotherapy&#xD;
&#xD;
               -  Interferon (e.g. Intron-A®)&#xD;
&#xD;
               -  Radiation therapy (Stereotactic radiotherapy, such as gamma knife, can be used ≥&#xD;
                  1 week and ≤ 6 months prior to registration)&#xD;
&#xD;
               -  Allergy desensitization injections&#xD;
&#xD;
               -  High doses of systemic corticosteroids, with the following qualifications and&#xD;
                  exceptions:&#xD;
&#xD;
                    -  In patients with adrenal or pituitary insufficiency replacement steroid&#xD;
                       doses are allowed; however, daily doses of 10 mg or more of prednisone (or&#xD;
                       equivalent) per day administered parenterally or orally are not allowed in&#xD;
                       patients with normal adrenal and pituitary function.&#xD;
&#xD;
                    -  Inhaled steroids (e.g.: Advair®, Flovent®, Azmacort®) are permitted at low&#xD;
                       doses (less than 500 mcg fluticasone per day, or equivalent) (76,77).&#xD;
&#xD;
                    -  Topical, nasal, and intra-articular corticosteroids are acceptable.&#xD;
&#xD;
               -  Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)&#xD;
&#xD;
               -  Interleukins (e.g. Proleukin®)&#xD;
&#xD;
               -  Any investigational medication&#xD;
&#xD;
               -  Targeted therapies specific for mutated BRAF or for MEK&#xD;
&#xD;
          -  Participants who are currently receiving nitrosoureas or who have received this&#xD;
             therapy within the preceding 6 weeks&#xD;
&#xD;
          -  Participants who are currently receiving a checkpoint molecule blockade therapy, or&#xD;
             who have received this therapy within the preceding 12 weeks.&#xD;
&#xD;
          -  Participants with known or suspected allergies to any component of the vaccine.&#xD;
&#xD;
          -  Participants may not have been vaccinated previously with any of the synthetic&#xD;
             peptides included in this protocol. Participants who have received vaccinations&#xD;
             containing agents other than the synthetic peptides included in this protocol and have&#xD;
             recurred during or after administration of the vaccine will be eligible to enroll 12&#xD;
             weeks following their last vaccination.&#xD;
&#xD;
          -  Pregnancy. Female participants of childbearing potential must have a negative&#xD;
             pregnancy test (urinary or serum beta-HCG) obtained within 2 weeks prior to&#xD;
             registration. Males and females must agree, in the consent form, to use effective&#xD;
             birth control methods during the course of vaccination.&#xD;
&#xD;
          -  Female participants must not be breastfeeding&#xD;
&#xD;
          -  Participants in whom there is a medical contraindication or potential problem in&#xD;
             complying with the requirements of the protocol in the opinion of the investigator.&#xD;
&#xD;
          -  Participants classified according to the New York Heart Association classification as&#xD;
             having Class III or IV heart disease (Appendix 4).&#xD;
&#xD;
          -  Participants with uncontrolled diabetes, defined as having a HgbA1c ≥ 7.5%.&#xD;
&#xD;
          -  Participants must not have had prior autoimmune disorders requiring cytotoxic or&#xD;
             immunosuppressive therapy, or autoimmune disorders with visceral involvement.&#xD;
             Participants with an active autoimmune disorder requiring these therapies are also&#xD;
             excluded. The following will not be exclusionary:&#xD;
&#xD;
               -  The presence of laboratory evidence of autoimmune disease (e.g. positive ANA&#xD;
                  titer) without symptoms&#xD;
&#xD;
               -  Clinical evidence of vitiligo&#xD;
&#xD;
               -  Other forms of depigmenting illness&#xD;
&#xD;
               -  Mild arthritis requiring NSAID medications&#xD;
&#xD;
          -  Participants who have another cancer diagnosis, except that the following diagnoses&#xD;
             will be allowed:&#xD;
&#xD;
               -  squamous cell cancer of the skin without known metastasis&#xD;
&#xD;
               -  basal cell cancer of the skin without known metastasis&#xD;
&#xD;
               -  carcinoma in situ of the breast (DCIS or LCIS)&#xD;
&#xD;
               -  carcinoma in situ of the cervix&#xD;
&#xD;
               -  any cancer without distant metastasis that has been treated successfully, without&#xD;
                  evidence of recurrence or metastasis for over 5 years&#xD;
&#xD;
          -  Participants with known addiction to alcohol or drugs who are actively taking those&#xD;
             agents, or participants with recent (within 1 year) or ongoing illicit IV drug use.&#xD;
&#xD;
          -  Body weight &lt; 110 pounds (without clothes) at registration, due to the amount and&#xD;
             frequency with which blood will be drawn.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L. Slingluff, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Center at the University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>April 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 29, 2021</results_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Director, Human Immune Therapy Center</investigator_title>
  </responsible_party>
  <keyword>peptide</keyword>
  <keyword>vaccine</keyword>
  <keyword>adjuvant</keyword>
  <keyword>polyICLC</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>Montanide ISA-51</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT02425306/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Open to accrual: May 12, 2015 Close to accrual: June 21, 2018&#xD;
Participants all enrolled at an academic medical center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A:6MHP + Montanide ISA-51</title>
          <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant</description>
        </group>
        <group group_id="P2">
          <title>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</title>
          <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
        </group>
        <group group_id="P3">
          <title>Arm C:6MHP + polyICLC + Montanide ISA-51</title>
          <description>Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant</description>
        </group>
        <group group_id="P4">
          <title>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</title>
          <description>Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A:6MHP + Montanide ISA-51</title>
          <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant</description>
        </group>
        <group group_id="B2">
          <title>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</title>
          <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
        </group>
        <group group_id="B3">
          <title>Arm C:6MHP + polyICLC + Montanide ISA-51</title>
          <description>Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant</description>
        </group>
        <group group_id="B4">
          <title>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</title>
          <description>Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="45" upper_limit="66"/>
                    <measurement group_id="B2" value="61" lower_limit="29" upper_limit="79"/>
                    <measurement group_id="B3" value="51" lower_limit="46" upper_limit="67"/>
                    <measurement group_id="B4" value="59" lower_limit="30" upper_limit="79"/>
                    <measurement group_id="B5" value="58" lower_limit="29" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AJCC stage (v7)</title>
          <description>Each participant was staged according to AJCC version 7 criteria at the time of study enrollment. Risk of death is generally higher for stage III than stage II, and within each stage, risk is higher for stage C than B than A. For those enrolled within 6 months of definitive therapy of the original diagnosis, the stage at diagnoses is used. For those enrolled after a subsequent recurrence or metastasis, the stage at recurrence was used.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>AJCC (v7) Stage IIA</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AJCC (v7) Stage IIB/IIC</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AJCC (v7) Stage III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AJCC (v7) Stage IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events</title>
        <description>Treatment-related adverse events, by CTCAE v4, Dose-limiting toxicities.</description>
        <time_frame>30 days after administration of the last dose of 6MHP or cyclophosphamide</time_frame>
        <population>All 48 participants , including 47 on part 1 and 1 on part 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A:6MHP + Montanide ISA-51</title>
            <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</title>
            <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
          </group>
          <group group_id="O3">
            <title>Arm C:6MHP + polyICLC + Montanide ISA-51</title>
            <description>Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant</description>
          </group>
          <group group_id="O4">
            <title>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</title>
            <description>Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Treatment-related adverse events, by CTCAE v4, Dose-limiting toxicities.</description>
          <population>All 48 participants , including 47 on part 1 and 1 on part 2.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity-CD4+ T Cell Responses</title>
        <description>CD4+ T cell responses to 6 MHP: durable helper T cell response to 6MHP at 2 or more consecutive timepoints in the PBMC.</description>
        <time_frame>through day 85</time_frame>
        <population>All ennrolled and treated patients on Parts 1 and 2 of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A:6MHP + Montanide ISA-51</title>
            <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</title>
            <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
          </group>
          <group group_id="O3">
            <title>Arm C:6MHP + polyICLC + Montanide ISA-51</title>
            <description>Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant</description>
          </group>
          <group group_id="O4">
            <title>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</title>
            <description>Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity-CD4+ T Cell Responses</title>
          <description>CD4+ T cell responses to 6 MHP: durable helper T cell response to 6MHP at 2 or more consecutive timepoints in the PBMC.</description>
          <population>All ennrolled and treated patients on Parts 1 and 2 of the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity-modification of the Tumor Microenvironment (Part 2 Only)</title>
        <description>increased infiltration of CD4+ and CD8+ T lymphocytes into melanoma metastases</description>
        <time_frame>through day 22</time_frame>
        <population>One patient enrolled on Part 2, was on Arm D.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A:6MHP + Montanide ISA-51</title>
            <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant</description>
          </group>
          <group group_id="O2">
            <title>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</title>
            <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
          </group>
          <group group_id="O3">
            <title>Arm C:6MHP + polyICLC + Montanide ISA-51</title>
            <description>Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant</description>
          </group>
          <group group_id="O4">
            <title>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</title>
            <description>Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity-modification of the Tumor Microenvironment (Part 2 Only)</title>
          <description>increased infiltration of CD4+ and CD8+ T lymphocytes into melanoma metastases</description>
          <population>One patient enrolled on Part 2, was on Arm D.</population>
          <units>cells per mm2 of tumor</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD8 T cells per mm2 in tumor pre-vaccine (day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8 T cells per mm2 in tumor day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T cells per mm2 of tumor prevaccine (day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 T cells per mm2 tumor day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="1102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity-CD8+ T Cell Responses</title>
        <description>CD8+ T cell responses to defined melanoma antigens</description>
        <time_frame>through day 85</time_frame>
        <posting_date>12/2021</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through administration of the last dose of 6MHP or mCy, plus 30 days. The scheduled dosing was designed such that the last does of 6MHP vaccine was to be given on day 78 and that the last dose of mCy was to be given on day 57. Thus, for a participant treated on schedule, and to completion, the AE period was 108 days. However, if either or both agents were given for a shorter period (eg held for toxicity), then the time period may be shorter.</time_frame>
      <desc>The study will be monitored continuously for treatment-related adverse events.&#xD;
A DLT is defined as any unexpected adverse event that is possibly, probably or definitely related to treatment and meets the following criteria:&#xD;
≥ Grade 3&#xD;
≥ Grade 1 ocular adverse events as defined below&#xD;
≥ Grade 2 allergic/autoimmune reactions as defined below Exceptions are made for small vaccine site ulceration, and for some transient systemic AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A:6MHP + Montanide ISA-51</title>
          <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant</description>
        </group>
        <group group_id="E2">
          <title>Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide</title>
          <description>Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
        </group>
        <group group_id="E3">
          <title>Arm C:6MHP + polyICLC + Montanide ISA-51</title>
          <description>Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant</description>
        </group>
        <group group_id="E4">
          <title>Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide</title>
          <description>Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:&#xD;
Day -6 (Cycle 1)&#xD;
Day 8 (Cycle 2)&#xD;
Day 22 (Cycle 3)&#xD;
Day 36 (Cycle 4)&#xD;
Day 50 (Cycle 5)&#xD;
6MHP: 6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides&#xD;
Montanide ISA-51: Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant&#xD;
polyICLC: polyICLC, local adjuvant&#xD;
Cyclophosphamide: Cyclophosphamide, systemic adjuvant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sepsis</sub_title>
                <description>Participant 22 developed septic joint near site of recent trauma, leading to grade 4 sepsis, considered only possibly related to cyclophosphamide but unrelated to the peptides or adjuvants. The patient was taken off study after 2 vaccines.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Mucositis, oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <description>Vaccine site local reaction</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin induration</sub_title>
                <description>Induration at vaccine sites</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <description>At sites of vaccines</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Craig Slingluff, MD, Professor of Surgery</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-924-9311</phone>
      <email>cls8h@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

